NCT06313593

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 186 (estimated)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

Conditions

• Myeloproliferative Neoplasms

Interventions

Type	Name	Description
DRUG	INCB160058	Oral; Tablet
DRUG	Standard disease-directed therapy	A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

Timeline

• Start date: 2024-08-08
• Primary completion: 2028-10-09
• Completion: 2028-10-09
• First posted: 2024-03-15
• Last updated: 2026-04-06

Locations

31 sites across 8 countries: United States, Canada, France, Germany, Italy, Norway, Switzerland, United Kingdom

Regulatory

• FDA-regulated drug study